You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Aberration-correcting Topologically Optimized Metasurface (ATOM)
SBC: PHYSICAL SCIENCES INC. Topic: HR001119S003524Metalenses, with their ability to arbitrarily control the amplitude and phase of light across a band of wavelengths, have the potential to disrupt imaging and communication systems which rely on traditional lenses to focus, collimate, and otherwise manipulate optical signals, and are under increasing pressure to operate with reduced size and weight. We propose to design, develop, and demonstrate a ...
STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency -
A Genes-to-Molecules Platform for Expanding Natural Product Diversity
SBC: Lassogen, Inc. Topic: NCCIHProject Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation
SBC: REBISCAN, Inc. Topic: NProject Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A novel device for cervical insufficiency in pregnant women
SBC: Cx Therapeutics, Inc Topic: NICHDAbstract In normal pregnancy, the cervix remains closed until term and then dilates under the influence of uterine contractions. In cases of cervical insufficiency (CI), the cervix dilates in the second trimester in the absence of uterine contractions, which leads to a preterm birth. Infants born prematurely are at risk of lifelong morbidities including chronic lung disease, feeding difficulties, ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids
SBC: SEACOAST SCIENCE, INC. Topic: NIDAAbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A novel platelet inhibitor from bloodfeeding hookworms
SBC: L2 DIAGNOSTICS LLC Topic: N/ADESCRIPTION (provided by applicant): Thromboembolic disease is a major cause of morbidity and mortality in the developed world. Because platelets play a critical role in the activation and propagation of thrombosis, they represent important targets for new anti-thrombotic drugs. A potent inhibitor of human platelet function has been isolated from the bloodfeeding hookworm, Ancylostoma caninum. ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
A novel role for Reelin therapeutics in inflammatory bowel disease
SBC: REELIN THERAPEUTICS, INC. Topic: 300Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A novel vaccine/adjuvant for Streptococcus pneumoniae
SBC: RxKinetix, Inc. Topic: N/AN/A
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Anti Inflammatory Membranes for Implantable Biosensors
SBC: APPLIED TISSUE AND MATERIALS, INC. Topic: N/ADESCRIPTION (provided by applicant): The prolonged inflammatory response to an implant is one of the primary causes for the failure to integrate implanted devices into tissue. The source of inflammation common to almost all implants is the foreign body response. Based on evidence in the literature and from our research team, the inflammatory response is mediated by the reactive oxygen species gene ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
A platform for engineering peptide ligase for building next generation peptide therapeutics.
SBC: SCRIBE BIOSCIENCES, INC. Topic: 400PROJECT SUMMARY There is an increased interest in peptide medicines in pharmaceutical research and development (Randamp;D) because peptides are recognized as highly selective and efficacious, and at the same time relatively safe and well tolerated. Chemo-enzymatic peptide synthesis (CEPS) using peptide ligases features excellent purity and yield, thus becoming an attractive method to replace tradi ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health